Literature DB >> 29173180

The Neutralizing Antibody Response to the HIV-1 Env Protein.

Penny L Moore1,2,3.   

Abstract

BACKGROUND: A vaccine able to elicit broadly neutralizing antibodies capable of blocking infection by global viruses has not been achieved, and remains a key public health challenge.
OBJECTIVE: During infection, a robust strain-specific neutralizing response develops in most people, but only a subset of infected people develop broadly neutralizing antibodies. Understanding how and why these broadly neutralizing antibodies develop has been a focus of the HIV-1 vaccine field for many years, and has generated extraordinary insights into the neutralizing response to HIV-1 infection.
RESULTS: This review describes the features, targets and developmental pathways of early strainspecific antibodies and later broadly neutralizing antibodies, and explores the reasons such broad antibodies are not more commonly elicited during infection.
CONCLUSION: The insights from these studies have been harnessed for the development of pioneering new vaccine approaches that seek to drive B cell maturation towards breadth. Overall, this review describes how findings from infected donors have impacted on active and passive immunization approaches that seek to prevent HIV-1 infection. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  HIV-1 envelope glycoprotein; broadly neutralizing antibodies; immunogens; passive immunity; viral escape; virus-host co-evolution.

Mesh:

Substances:

Year:  2018        PMID: 29173180      PMCID: PMC6234226          DOI: 10.2174/1570162X15666171124122044

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  93 in total

1.  Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire.

Authors:  Bryan S Briney; Jordan R Willis; Mark D Hicar; James W Thomas; James E Crowe
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

2.  Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.

Authors:  Evan M Cale; Jason Gorman; Nathan A Radakovich; Ema T Crooks; Keiko Osawa; Tommy Tong; Jiaqi Li; Raju Nagarajan; Gabriel Ozorowski; David R Ambrozak; Mangai Asokan; Robert T Bailer; Anthony K Bennici; Xuejun Chen; Nicole A Doria-Rose; Aliaksandr Druz; Yu Feng; M Gordon Joyce; Mark K Louder; Sijy O'Dell; Courtney Oliver; Marie Pancera; Mark Connors; Thomas J Hope; Thomas B Kepler; Richard T Wyatt; Andrew B Ward; Ivelin S Georgiev; Peter D Kwong; John R Mascola; James M Binley
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

3.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 4.  Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Authors:  Penny L Moore; Carolyn Williamson; Lynn Morris
Journal:  Trends Microbiol       Date:  2015-01-05       Impact factor: 17.079

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

6.  HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant.

Authors:  Cassandra A Simonich; Katherine L Williams; Hans P Verkerke; James A Williams; Ruth Nduati; Kelly K Lee; Julie Overbaugh
Journal:  Cell       Date:  2016-06-23       Impact factor: 41.582

7.  Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity.

Authors:  B S Briney; J R Willis; J E Crowe
Journal:  Genes Immun       Date:  2012-06-21       Impact factor: 2.676

8.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

9.  Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein.

Authors:  Anna-Janina Behrens; Snezana Vasiljevic; Laura K Pritchard; David J Harvey; Rajinder S Andev; Stefanie A Krumm; Weston B Struwe; Albert Cupo; Abhinav Kumar; Nicole Zitzmann; Gemma E Seabright; Holger B Kramer; Daniel I R Spencer; Louise Royle; Jeong Hyun Lee; Per J Klasse; Dennis R Burton; Ian A Wilson; Andrew B Ward; Rogier W Sanders; John P Moore; Katie J Doores; Max Crispin
Journal:  Cell Rep       Date:  2016-03-10       Impact factor: 9.423

10.  Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.

Authors:  Jinal N Bhiman; Colin Anthony; Nicole A Doria-Rose; Owen Karimanzira; Chaim A Schramm; Thandeka Khoza; Dale Kitchin; Gordon Botha; Jason Gorman; Nigel J Garrett; Salim S Abdool Karim; Lawrence Shapiro; Carolyn Williamson; Peter D Kwong; John R Mascola; Lynn Morris; Penny L Moore
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  16 in total

1.  Computational tools for modern vaccine development.

Authors:  Andaleeb Sajid; Yogendra Singh; Pratyoosh Shukla
Journal:  Hum Vaccin Immunother       Date:  2019-12-18       Impact factor: 3.452

Review 2.  Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.

Authors:  Yukako Ohyama; Kazuki Nakajima; Matthew B Renfrow; Jan Novak; Kazuo Takahashi
Journal:  Expert Rev Proteomics       Date:  2020-05-28       Impact factor: 3.940

3.  New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure.

Authors:  Hui Li; Shuyi Wang; Fang-Hua Lee; Ryan S Roark; Alex I Murphy; Jessica Smith; Chengyan Zhao; Juliette Rando; Neha Chohan; Yu Ding; Eunlim Kim; Emily Lindemuth; Katharine J Bar; Ivona Pandrea; Cristian Apetrei; Brandon F Keele; Jeffrey D Lifson; Mark G Lewis; Thomas N Denny; Barton F Haynes; Beatrice H Hahn; George M Shaw
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

4.  Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice.

Authors:  Milan Kuchař; Petr Kosztyu; Veronika Daniel Lišková; Jiří Černý; Hana Petroková; Eliška Vróblová; Michal Malý; Lucie Vaňková; Michal Křupka; Leona Rašková Kafková; Pavlína Turánek Knotigová; Jarmila Dušková; Jan Dohnálek; Josef Mašek; Jaroslav Turánek; Milan Raška; Petr Malý
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 5.  Glycosylation in health and disease.

Authors:  Colin Reily; Tyler J Stewart; Matthew B Renfrow; Jan Novak
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 42.439

Review 6.  Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies.

Authors:  Jorge Carrillo; Bonaventura Clotet; Julià Blanco
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

7.  Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity.

Authors:  Dai Zhang; Sen Zou; Yuanyuan Hu; Jiali Hou; Xintao Hu; Li Ren; Liying Ma; Xiang He; Yiming Shao; Kunxue Hong
Journal:  Front Microbiol       Date:  2019-05-24       Impact factor: 5.640

Review 8.  Impact of HIV-1 Diversity on Its Sensitivity to Neutralization.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Martine Braibant; Francis Barin
Journal:  Vaccines (Basel)       Date:  2019-07-25

9.  Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth.

Authors:  Ryan S Roark; Hui Li; Wilton B Williams; Hema Chug; Rosemarie D Mason; Jason Gorman; Shuyi Wang; Fang-Hua Lee; Juliette Rando; Mattia Bonsignori; Kwan-Ki Hwang; Kevin O Saunders; Kevin Wiehe; M Anthony Moody; Peter T Hraber; Kshitij Wagh; Elena E Giorgi; Ronnie M Russell; Frederic Bibollet-Ruche; Weimin Liu; Jesse Connell; Andrew G Smith; Julia DeVoto; Alexander I Murphy; Jessica Smith; Wenge Ding; Chengyan Zhao; Neha Chohan; Maho Okumura; Christina Rosario; Yu Ding; Emily Lindemuth; Anya M Bauer; Katharine J Bar; David Ambrozak; Cara W Chao; Gwo-Yu Chuang; Hui Geng; Bob C Lin; Mark K Louder; Richard Nguyen; Baoshan Zhang; Mark G Lewis; Donald D Raymond; Nicole A Doria-Rose; Chaim A Schramm; Daniel C Douek; Mario Roederer; Thomas B Kepler; Garnett Kelsoe; John R Mascola; Peter D Kwong; Bette T Korber; Stephen C Harrison; Barton F Haynes; Beatrice H Hahn; George M Shaw
Journal:  Science       Date:  2020-11-19       Impact factor: 47.728

10.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

Authors:  P J Klasse; Thomas J Ketas; Christopher A Cottrell; Gabriel Ozorowski; Gargi Debnath; Diawoye Camara; Erik Francomano; Pavel Pugach; Rajesh P Ringe; Celia C LaBranche; Marit J van Gils; Christine A Bricault; Dan H Barouch; Shane Crotty; Guido Silvestri; Sudhir Kasturi; Bali Pulendran; Ian A Wilson; David C Montefiori; Rogier W Sanders; Andrew B Ward; John P Moore
Journal:  PLoS Pathog       Date:  2018-02-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.